

Technology Appraisal Committee Meeting (Committee A)
10 Spring Gardens, London SW1A 2BU

Minutes: Confirmed

Date and Time: Thursday 16 August 2018, 10:00 – 16:00

Present:	1. Dr Jane Adam (Chair) 2. Professor Iain Squire (Vice-Chair) 3. Dr Steve Edwards 4. Dr Rita Faria 5. Mr Adrian Griffin 6. Ms Pamela Rees 7. Dr Mohit Sharma 8. Dr Brian Shine 9. Dr John Watkins 10. Professor Olivia Wu 11. Dr Rachel Hobson 12. Dr Graham Ash 13. Min Ven Teo 14. Mr Stephen Sharp 15. David Chandler	Present for all notes Present for all notes Present for notes 7 to 11 Present for all notes Present for notes 1 to 6 Present for all notes Present for all notes
-----------------	--	--

In attendance:

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Thomas Feist	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Gavin Kenny	Assistant Project Manager, National Institute for Health and Care Excellence	Present for all notes
Juliet Kenny	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 6
Eleanor Donegan	Technical Adviser, National Institute for	Present for notes 1 to 6

	Health and Care Excellence	
Aminata Thiam	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 7 to 11
Victoria Kelly	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 7 to 11
Steve Edwards	BMJ-TAG, Evidence Review Group	Present for notes 1 to 3
Peter Cain	BMJ-TAG, Evidence Review Group	Present for notes 1 to 3
Victoria Wakefield	BMJ-TAG, Evidence Review Group	Present for notes 1 to 3
Jo Picot	SHTAC, Evidence Review Group	Present for notes 7 to 8
Jo Lord	SHTAC, Evidence Review Group	Present for notes 7 to 8
Dr James Larkin	Clinical expert, Consultant Medical Oncologist, Royal Marsden	Present for notes 1 to 3
Dr Louise Fearfield	Clinical expert, Consultant Dermatologist, Royal Marsden and ChelWest	Present for notes 1 to 3
Dr Patrick Allen	Clinical expert, Consultant Gastroenterologist, Ulster Hospital	Present for notes 7 to 8
Dianne Cannon	Patient expert	Present for notes 1 to 3
Charlotte Hughes	Patient expert	Present for notes 7 to 8
Shirley Leather	Patient expert	Present for notes 7 to 8
Professor Peter Clark	Cancer Drugs Fund Clinical Lead	Present for notes 1 to 6

Non-public attendees:

Ana Uribe Echeverry	Corporate Office Coordinator, NICE	Present for all notes
Chloe Kastoryano	Public Involvement Adviser, NICE	Present for all notes
Dr Alice Turnbull	Public Health England	Present for notes 1 to 6
Rebecca Smittenaar	Public Health England	Present for notes 1 to 6
Martine Bomb	Public Health England	Present for notes 1 to 6
Professor Stephen Munn	NICE guest	Present for notes 1 to 6
Emily Crowe	Scientific Advice NICE	Present for notes 7 to 11
Victoria Kelly	Technology Appraisals, NICE	Present for notes 1 to 6
Thomas Strong	Cancer Drugs Fund, NICE	Present for notes 1 to 6

Notes

Any other business

1. None.

Appraisal of nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316]

Part 1 – Open session

2. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Bristol-Myers Squibb.
3. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.
 - 3.1. No conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
5. The committee decision was based on consensus.
6. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of tofacitinib for previously treated active ulcerative colitis [ID1218]

Part 1 – Open session

7. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Pfizer.
8. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
 - 8.1. Adrian Griffin declared a direct financial interest as his employer owns infliximab, one of the comparator treatments for this appraisal. Therefore he did not take part in this part of the meeting.
 - 8.2. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

9. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
10. The committee decision was based on consensus.
11. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.